OTICAIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTICAIR (OTICAIR).
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
| Metabolism | Ciprofloxacin is metabolized via CYP1A2 to desethylene ciprofloxacin and other metabolites; fluocinolone acetonide undergoes hepatic metabolism primarily via CYP3A4. |
| Excretion | Renal: 85% unchanged; biliary/fecal: 10% |
| Half-life | 4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min) |
| Protein binding | 85-90% bound primarily to albumin |
| Volume of Distribution | 0.8 L/kg; indicates moderate tissue distribution |
| Bioavailability | Oral: 70% (first-pass metabolism reduces absorption) |
| Onset of Action | Oral: 30-60 minutes; intravenous: immediate |
| Duration of Action | 6-8 hours; extended-release formulations provide 12-24 hour coverage |
| Molecular Weight | 288.26 Da (specific value for oticair, assumed; verify exact compound) |
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children 6 months and older: 1 spray into each affected ear twice daily for 7 days. Weight-based adjustments not required. |
| Geriatric use | No specific dose adjustment for elderly patients; use standard adult dosing. |
| 1st trimester | Insufficient data in humans; animal studies show no risk at therapeutic doses. Use only if clearly needed. |
| 2nd trimester | No known risks; avoid prolonged use near term due to potential for premature ductus arteriosus closure. |
| 3rd trimester | Avoid in third trimester; NSAIDs may cause premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for OTICAIR (OTICAIR).
| Placental transfer | Crosses placenta; animal studies show minimal transfer, but human data limited. |
| Breastfeeding | Excreted in breast milk in low amounts; likely safe with caution. Monitor infant for diarrhea or rash. Consider lowest effective dose for shortest duration. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to oticair or any componentActive infection at application siteTympanic membrane perforation
| Precautions | Ototoxicity: Caution in patients with perforated tympanic membrane or chronic otitis media due to risk of hearing loss, Hypersensitivity: Discontinue if rash or allergic reaction occurs, Superinfection: Prolonged use may result in fungal or bacterial overgrowth, Corticosteroid effects: Avoid prolonged use due to risk of adrenal suppression or local immunosuppression |
| Food/Dietary | No known significant food interactions. Avoid alcohol as it may exacerbate dizziness. |
| Clinical Pearls |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Pregnancy Category C. Inadequate human data; animal studies show fetal harm at high doses. First trimester: risk of major malformations unknown. Second and third trimesters: potential for fetal respiratory depression and ototoxicity if absorbed systemically. Avoid use during pregnancy unless benefits outweigh risks. |
| Fetal Monitoring | Monitor maternal renal function and hearing (audiometry) with prolonged use. Fetal ultrasound to assess growth and amniotic fluid volume if systemic absorption suspected. |
| Fertility Effects | Animal studies show no adverse effects on fertility. Human data lacking. |
| Oticair (ciprofloxacin 0.3% + fluocinolone acetonide 0.025%) otic solution is indicated for otitis externa. For maximum efficacy, ensure the ear canal is clear of debris before instillation. The patient should lie with the affected ear up for 5 minutes after dosing. Avoid use in patients with perforated tympanic membrane due to risk of ototoxicity from fluocinolone. Ciprofloxacin may cause tendonitis; monitor for tendon pain or swelling. |
| Patient Advice | Use exactly as prescribed; do not skip doses or stop early. · Warm the bottle in your hands for 1-2 minutes before use to avoid dizziness from cold liquid. · Lie on your side with the affected ear up for 5 minutes after instillation. · Do not touch the dropper tip to any surface to avoid contamination. · Inform your doctor if you experience ear pain, new drainage, or hearing loss. · Avoid swimming or getting water in the ear during treatment. |